Acceleron Pharma Inc. (XLRN)

44.90
0.33 0.74
NASDAQ : Health Technology
Prev Close 44.57
Open 44.34
Day Low/High 44.34 / 46.39
52 Wk Low/High 37.01 / 56.91
Volume 225.09K
Avg Volume 278.50K
Exchange NASDAQ
Shares Outstanding 53.08M
Market Cap 2.30B
EPS -2.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Acceleron To Host Conference Call And Webcast To Review MEDALIST And BELIEVE Phase 3 Trial Presentations Of Luspatercept At The 60th American Society Of Hematology Annual Meeting

Acceleron To Host Conference Call And Webcast To Review MEDALIST And BELIEVE Phase 3 Trial Presentations Of Luspatercept At The 60th American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will host a conference call and live audio webcast on Monday,...

Acceleron To Participate In Two Upcoming Healthcare Investor Conferences

Acceleron To Participate In Two Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare...

Acceleron Announces Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension At The 2018 American Heart Association Scientific Session

Acceleron Announces Preclinical Presentations On Sotatercept In Pulmonary Arterial Hypertension At The 2018 American Heart Association Scientific Session

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three preclinical presentations on sotatercept in...

Acceleron Announces That Phase 3 Results From The MEDALIST And BELIEVE Trials Of Luspatercept Will Be Presented At The 60th American Society Of Hematology Annual Meeting

Acceleron Announces That Phase 3 Results From The MEDALIST And BELIEVE Trials Of Luspatercept Will Be Presented At The 60th American Society Of Hematology Annual Meeting

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that results from the MEDALIST and BELIEVE Phase 3 trials of luspatercept in patients with low-to-intermediate risk myelodysplastic syndromes (MDS) and transfusion-dependent beta-thalassemia,...

Acceleron Reports Third Quarter 2018 Operating And Financial Results

Acceleron Reports Third Quarter 2018 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter...

First Week Of XLRN May 2019 Options Trading

First Week Of XLRN May 2019 Options Trading

Investors in Acceleron Pharma, Inc. saw new options become available this week, for the May 2019 expiration.

Acceleron To Webcast Third Quarter 2018 Operating And Financial Results On October 30, 2018

Acceleron To Webcast Third Quarter 2018 Operating And Financial Results On October 30, 2018

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Tuesday, October 30, 2018 at 4:30 p.

Acceleron To Host Pulmonary Arterial Hypertension Research And Development Deep Dive Event On November 16, 2018 In New York City

Acceleron To Host Pulmonary Arterial Hypertension Research And Development Deep Dive Event On November 16, 2018 In New York City

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will webcast a live presentation from its Pulmonary Arterial...

Acceleron Announces Presentations On ACE-083 At The 23rd International Annual Congress Of The World Muscle Society

Acceleron Announces Presentations On ACE-083 At The 23rd International Annual Congress Of The World Muscle Society

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver poster presentations on ACE-083 from Part 1 of each its...

Acceleron To Participate In Three Upcoming Healthcare Investor Conferences

Acceleron To Participate In Three Upcoming Healthcare Investor Conferences

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in three upcoming healthcare...

Acceleron Reports Second Quarter 2018 Operating And Financial Results

Acceleron Reports Second Quarter 2018 Operating And Financial Results

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the second quarter...

Notable Tuesday Option Activity: XLRN, ARAY, X

Notable Tuesday Option Activity: XLRN, ARAY, X

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acceleron Pharma, Inc. , where a total volume of 3,811 contracts has been traded thus far today, a contract volume which is representative of approximately 381,100 underlying shares (given that every 1 contract represents 100 underlying shares).

Acceleron To Webcast Second Quarter 2018 Operating And Financial Results On August 2, 2018

Acceleron To Webcast Second Quarter 2018 Operating And Financial Results On August 2, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.

Acceleron Announces Preliminary Results From Part 1 Of The ACE-083 Phase 2 Trial In Patients With Charcot-Marie-Tooth Disease At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron Announces Preliminary Results From Part 1 Of The ACE-083 Phase 2 Trial In Patients With Charcot-Marie-Tooth Disease At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced positive preliminary results from Part 1 of the Phase 2 clinical trial...

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Receives FDA Orphan Drug Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted...

Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia

Celgene And Acceleron Announce Luspatercept Achieved Primary And All Key Secondary Endpoints In Phase III 'BELIEVE' Study In Adults With Transfusion-Dependent Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (BELIEVE).

Robert K. Zeldin, M.D., Named Chief Medical Officer, Acceleron Pharma Inc.

Robert K. Zeldin, M.D., Named Chief Medical Officer, Acceleron Pharma Inc.

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the appointment of Robert K.

Celgene And Acceleron Announce Luspatercept Achieved Primary And Key Secondary Endpoints In Phase III 'MEDALIST' Study In Patients With Low-to-Intermediate Risk Myelodysplastic Syndromes

Celgene And Acceleron Announce Luspatercept Achieved Primary And Key Secondary Endpoints In Phase III 'MEDALIST' Study In Patients With Low-to-Intermediate Risk Myelodysplastic Syndromes

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind, multi-center clinical study (MEDALIST).

Acceleron To Present Preliminary Data On ACE-083 At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron To Present Preliminary Data On ACE-083 At The 2018 Annual Meeting Of The Peripheral Nerve Society

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver oral and poster presentations on ACE-083 from the...

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Beta-Thalassemia At The 23rd Congress Of The European Hematology Association

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Beta-Thalassemia At The 23rd Congress Of The European Hematology Association

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the ongoing Phase 2 trials of luspatercept in...

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The ASCO 2018 Annual Meeting

Acceleron Announces Updated Results From Ongoing Phase 2 Trials Of Luspatercept In Myelodysplastic Syndromes At The ASCO 2018 Annual Meeting

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the Phase 2 trials of luspatercept in patients with...

Acceleron Announces Initiation Of PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Acceleron Announces Initiation Of PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the initiation of the PULSAR Phase 2 trial of sotatercept for the...

Acceleron Announces Presentations On Luspatercept At The 23rd Congress Of The European Hematology Association

Acceleron Announces Presentations On Luspatercept At The 23rd Congress Of The European Hematology Association

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspatercept at the 23 rd...

Noteworthy Friday Option Activity: XLRN, VRAY, AKRX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acceleron Pharma, Inc. , where a total of 2,988 contracts have traded so far, representing approximately 298,800 underlying shares.

Acceleron Reports First Quarter 2018 Operating And Financial Results

Acceleron Reports First Quarter 2018 Operating And Financial Results

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter...

Acceleron To Participate In Two Healthcare Investor Conferences In May

Acceleron To Participate In Two Healthcare Investor Conferences In May

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare...

Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy (FSHD)

Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy (FSHD)

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the U.

Acceleron To Webcast First Quarter 2018 Operating And Financial Results On May 8, 2018

Acceleron To Webcast First Quarter 2018 Operating And Financial Results On May 8, 2018

Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.

Acceleron Announces ACE-083 Phase 2 Trial Presentation At The American Academy Of Neurology 70th Annual Meeting

Acceleron Announces ACE-083 Phase 2 Trial Presentation At The American Academy Of Neurology 70th Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that preliminary results from the ongoing Phase 2 trial of ACE-083 in...

Acceleron Announces Presentations On Lead Product Candidate Luspatercept At The 2018 American Society Of Clinical Oncology Annual Meeting

Acceleron Announces Presentations On Lead Product Candidate Luspatercept At The 2018 American Society Of Clinical Oncology Annual Meeting

Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts on lead product candidate luspatercept will be...

TheStreet Quant Rating: D+ (Sell)